P2RY12 and COVID-19: Similarly, the RECOVERY trial showed no added benefit from combining aspirin with standard anticoagulant therapy in hospitalized COVID-19 patients (97), and another RCT demonstrated no mortality benefit from the P2Y12 inhibitor ticagrelor, when combined with heparin, in non-critically ill COVID-19 patients (98).